Yahya Samadi: Luspatercept Shows Promise in Reducing Transfusion Burden in β-Thalassemia
Yahya Samadi, Research Assistant at Khatam-Al-nabieen University, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Annals of Hematology, adding:
“New Publication Alert!
I am delighted to share that our systematic review and meta-analysis, ‘Outcomes with Luspatercept in Patients with β-Thalassemia: A Systematic Review and Meta-analysis,’ has been published in Annals of Hematology.
This study evaluated the efficacy and safety of luspatercept in adults with β-thalassemia, demonstrating that it significantly reduces red blood cell transfusion burden while maintaining an acceptable safety profile.
These findings support luspatercept as an effective therapeutic option that may improve patients’ quality of life and reduce complications associated with chronic transfusions.
I am honored to have contributed to this collaborative international research and to serve as the corresponding author on this publication.
I sincerely thank all my co-authors for their dedication and collaboration throughout this project.
I also appreciate everyone who has supported my research journey.”
Title: Outcomes with luspatercept in patients with β-thalassemia: a systematic review and meta-analysis
Authors: Nihal Babiker, Eslam Abady, Hafsa Shahid, Wania Ur Rehman, Faris Babker, Menna Sarhan, Hind El Azzazi, Mohamedelborae Abdalgafar Elimam Mohamed, Hafiz Muhammad Hannan Javed, Yahya Samadi
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 27, 2026, 13:03Margarida Marreiros: Supporting Excellence in Hemostasis Testing
-
Jun 27, 2026, 12:44Maia Meier: Turning Achievement into Advocacy for Women with Bleeding Disorders
-
Jun 27, 2026, 12:38BSH Guideline for the Estimation of Fetomaternal Haemorrhage
-
Jun 27, 2026, 12:34Vishnu K: The Growing Role of RET-He in Modern Hematology
-
Jun 27, 2026, 12:33María Gabriela Muñoz: TOAST Criteria and Outcomes in Ischemic Stroke
-
Jun 27, 2026, 12:17Navid Radfar: Moving Beyond CHA₂DS₂-VASc and De-Risking Atrial Fibrillation
-
Jun 27, 2026, 12:11Gianluca De Rubeis: A Safer Approach to Antiplatelet Timing in Endovascular Aneurysm Treatment
-
Jun 27, 2026, 12:09Mapillar Dahn: Empowering Sickle Cell Warriors Through Awareness and Support
-
Jun 27, 2026, 12:00Ney Carter Borges: FAVOR III China Demonstrates a 37% Reduction in Myocardial Infarction with QFR Guidance